Sorin Group, the largest European cardiovascular company and world leader in medical technologies for cardiac surgery, announced today the publication of 21-year durability data of its Mitroflow™ Aortic Pericardial Heart Valve in the September issue of the Journal Of Thoracic And Cardiovascular Surgery.
The Mitroflow Aortic Pericardial Heart Valve, a biological heart valve, was introduced in Europe in 1982. In over 20 years of clinical use it has demonstrated superior hemodynamic performance and proven long-term durability in a design recognized by surgeons worldwide for its ease of implant in even the most challenging anatomies.
Biological valves are increasingly used to replace diseased native valves. They are designed to improve the patient’s quality of life by obviating the need for lifelong anticoagulation therapy.
“To date, the Mitroflow pericardial bioprosthesis has demonstrated excellent durability at 21 years. I am particularly happy to be able to provide long-term durability to my patients”, said Prof. Charles Yankah, Associate Professor of Surgery, Charité Medical University, Berlin, Germany and Consultant CardioThoracic and Vascular Surgeon, Berlin Herzzentrum, Berlin, Germany.
“The 21 year data represents the longest patient follow up ever published in the history of pericardial valves and represents a new benchmark for all pericardial valves today,” said Stefano Di Lullo, President Heart Valves Business Unit of Sorin Group. “We are delighted that this peer-reviewed scientific journal confirms the proven long-term durability of the Mitroflow valve in addition to its already recognized best-in-class hemodynamic performance,” he added.
EATCS attendees will be able to visit the Sorin Group exhibit (Booth N°2.28) featuring the industry’s broadest array of therapeutic heart valve solutions available to the surgeon community.